ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RSPI RespireRx Pharmaceuticals Inc (PK)

0.0009
0.00 (0.00%)
08 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
RespireRx Pharmaceuticals Inc (PK) USOTC:RSPI OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0009 0.0001 0.05 0.00 11:01:06

VIP EARLY ALERT SERVICE Offered by Elite Traders Group for Limited Time, 11 Positions Remain. Only $29.95/Month or $199.00/Year

26/06/2013 1:30pm

InvestorsHub NewsWire


One of the most frequently asked questions is, "does your VIP group receive alerts ahead of the crowd?" and the answer is YES. We offer our VIP's early alerts and VIP only alerts that the rest of the group is not privy to. VIP early alerts and VIP only alerts are provided via our private VIP twitter feed which is not viewable by the public. This allows us to keep VIP alerts within our exclusive group and not accessible by third parties. Other VIP pre-promotion alert services send by email which goes viral within minutes and really is not a VIP alert at all. We typically send the new feature alerts to our premium members 30 minutes to 24 hours in advance. This gives our VIP's more time to conduct their due diligence and avoid chasing the price action. Our group is growing at an exponential rate and this service will be going up in price soon and eventually closed for good. We currently have 89 VIP's (verifiable at this twitter link: https://twitter.com/FPPVIP) and will not exceed 100.

Use the following link now to increase your chances of success. http://www.firstpennypicks.com/vip-membership/

Cortex Pharmaceuticals, Inc. (OTCPINK: CORX) discovers, develops, and commercializes pharmaceuticals for the treatment of neurodegenerative diseases and other neurological and psychiatric disorders. The Company develops a family of chemical compounds, known as Ampakines, that enhance the activity of the AMPA-type glutamate receptor. For a full technical analysis use the following link: http://bit.ly/TechnicalReport

XOMA Corporation (NASDAQ: XOMA), incorporated on November 31, 2011, is engaged in the discovery and development of antibody-based therapeutics. The Company's lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company's preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. For a full technical analysis use the following link: http://bit.ly/TechnicalReport

Star Scientific, Inc. (NASDAQ: STSI), incorporated on June 24, 1985, is engaged in the manufacturing and production of dietary supplements. The Company's operating subsidiaries manufacture, distribute and sell consumer products and dietary supplements. Its segment includes dietary supplements. Through its Rock Creek Pharmaceuticals, Inc. (Rock Creek) subsidiary, the Company is engaged in the manufacture, sale, marketing and development of non-nicotine nutraceutical, dietary supplements: Anatabloc, for anti-inflammatory support; the manufacture, sale and marketing of a cosmetic facial cream, and the development of other nutraceuticals, dietary supplements and pharmaceutical products. For a full technical analysis use the following link: http://bit.ly/TechnicalReport

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), incorporated on on April 12, 1991, is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD's first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer. For a full technical analysis use the following link: http://bit.ly/TechnicalReport

http://www.Firstpennypicks.com was developed as a beacon of hope in the micro-cap stock newsletter industry. We always hand-pick our alerts as opposed to biased advertising. Our service typically covers the hottest penny stocks for a longer term than one day offering more potential profit situations. This is why we are the fastest growing community of micro-cap traders on the web.

To Receive More Reports like this one Subscribe free at http://www.FirstPennyPicks.com
For mobile alerts text "FPPALERTS" to 25827

Disclaimer: Firstpennypicks.com is owned by Elite traders Group LLC. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. First Penny Picks has not been compensated for this report.

SOURCE: Elite Traders Group LLC
Contact: Editor@FirstPennyPicks.com



1 Year RespireRx Pharmaceuticals (PK) Chart

1 Year RespireRx Pharmaceuticals (PK) Chart

1 Month RespireRx Pharmaceuticals (PK) Chart

1 Month RespireRx Pharmaceuticals (PK) Chart

Your Recent History

Delayed Upgrade Clock